Cancer Genetics – News and Features

Researchers have revealed how IDH mutations in gliomas act as a "ticking time bomb," initiating slow growth before genetic mutations drive aggressive cancer progression. The study highlights epigenetic immune suppression and cellular shifts.

T-cell dysfunction linked to obesity prevents T cells from detecting tumor cells, increasing cancer risk.

New research shows that a single BRCA1 mutation is sufficient to promote breast cancer by making breast cells more susceptible to tumor growth. This finding redefines the two-hit model of cancer development.

A new model for studying breast cancer could help researchers better understand why and where it metastasizes.

Stanford Medicine researchers discovered that extrachromosomal DNA (ecDNA) significantly drives cancer growth. By analyzing nearly 15,000 human cancers, they found that ecDNAs impact tumor behavior and can be targeted with therapies.

Researchers have identified how mutations to CDK12 drive prostate cancer development and reported a promising treatment that targets the gene.

Researchers have identified 22 pesticides consistently associated with the incidence of prostate cancer in the United States, with 4 of the pesticides also linked with prostate cancer mortality.

A study introduces a modified metal-organic framework (MOF) capable of capturing benzene, a known carcinogen, from polluted air. The new material, MIL-125-Zn, demonstrates significant efficiency in removing benzene.

Researchers have shed new light on the role of p53 in the pathogenesis of ulcerative colitis, which is linked to an increased colon cancer risk.

Compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer’s disease in people with type 2 diabetes, according to a new study.